PharmaLive
ROCHESTER, N.Y., Jan. 24, 2007 - Bausch & Lomb announced today that the Centers for Medicare and Medicaid Services (CMS) has established a product specific J-Code for the Retisert fluocinolone acetonide intravitreal implant 0.59 mg. The Retisert implant was approved as a single indication orphan drug by the U.S. Food and Drug Administration for the treatment of chronic noninfectious posterior segment uveitis, a sight threatening inflammatory disease and a major cause of blindness in patients 20-50 years of age.